US4758569A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Doxazosin as an anti-atherosclerosis agent
Assignee: Pfizer Inc
•
Filing: 1987-08-26
•
Granted: 1988-07-19
•
Expires: 2007-08-26
Abstract
Abstract This invention relates to the use of doxazosin or a pharmaceutically acceptable acid addition salt thereof as an agent for retarding the development of atherosclerosis in a mammal, especially for reducing atherosclerotic plaque involvement and for retarding and reducing both the fibrosis and lipid deposition of developing atherosclerotic plaques associated with atherosclerosis.
Inventors
- 👤 Archie C. Swindell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 09:00
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61P; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
50 words
A method of suppressing fibrosis and lipid deposition of atherosclerotic lesions and of reducing atherosclerotic lesions in a mammal having atherosclerosis which comprises administering to said mammal an atherosclerotic lesion reducing and a fibrosis lesion and lipid deposition suppressing amount of doxazosin or a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Independent Claim
50 words
A method of suppressing fibrosis and lipid deposition of atherosclerotic lesions and of reducing atherosclerotic lesions in a mammal having atherosclerosis which comprises administering to said mammal an atherosclerotic lesion reducing and a fibrosis lesion and lipid deposition suppressing amount of doxazosin or a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
9 words
The method of claim 1 wherein doxazosin is administered.
Claim 4
Dependent Claim
19 words
The method of claim 1 wherein the doxazosin or a pharmaceutically acceptable acid addition salt thereof is administered orally.
Claim 5
Dependent Claim
19 words
The method of claim 1 wherein the doxazosin or a pharmaceutically acceptable acid addition salt thereof is administered intraperitoneally.
Claim 6
Dependent Claim
19 words
The method of claim 1 wherein the doxazosin or a pharmaceutically acceptable acid addition salt thereof is administered transdermally.
Claim 7
Dependent Claim
19 words
The method of claim 1 wherein the doxazosin or a pharmaceutically acceptable acid addition salt thereof is administered parenterally.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-07-19 | 1992-01-18 | 1992-07-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-07-19 | 1996-01-18 | 1996-07-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-07-19 | 2000-01-18 | 2000-07-19 | $7700.00 | Window Closed / Lapsed |